Pathogenesis of Graves' ophthalmopathy: The role of autoantibodies

Thyroid

Volumn 17, Issue 10, 2007, Pages 1013-1018

  Khoo, Teck Kim ^a   Bahn, Rebecca S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ABATACEPT; ADALIMUMAB; ALEFACEPT; AUTOANTIBODY; ETANERCEPT; HYALURONIC ACID; INFLIXIMAB; MESSENGER RNA; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SOMATOMEDIN C RECEPTOR; THYROTROPIN RECEPTOR;

ADIPOGENESIS; ADIPOSE TISSUE; AUTOIMMUNITY; EDEMA; ENDOCRINE OPHTHALMOPATHY; EXTRAOCULAR MUSCLE; FIBROBLAST; HORMONE SYNTHESIS; HUMAN; INFLAMMATION; LIPID STORAGE; MUSCLE MASS; ORBIT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

AUTOANTIBODIES; FIBROBLASTS; GRAVES OPHTHALMOPATHY; HUMANS; OCULOMOTOR MUSCLES; RECEPTOR, IGF TYPE 1; RECEPTORS, THYROTROPIN;

EID: 35948965186     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0185     Document Type: Review

References (44)

1. Bahn RS, Heufelder AE 1993 Pathogenesis of Graves' ophthalmopathy. N Engl J Med 329:1468-1475.
2. Prabhakar BS, Bahn RS, Smith TJ 2003 Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 24:802-835.
3. Garrity JA, Bahn RS 2006 Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 142:147-153.
4. Weetman AP, Cohen S, Gatter KC, Fells P, Shine B 1989 Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 75:222-227.
5. Sorisky A, Pardasani D, Gagnon A, Smith TJ 1996 Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab 81:3428-3431.
6. Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, Sorisky A 2002 Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 87:385-392.
7. Smith TJ, Bahn RS, Gorman CA, Cheavens M 1991 Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured human retroocular fibroblasts. J Clin Endocrinol Metab 72:1169-1171.
8. Smith TJ, Wang HS, Evans CH 1995 Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am J Physiol: Cell Physiol 268:C382-C388.
9. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK, O'Rahilly S 1997 Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153.
10. Khoo DH, Eng PH, Ho SC, Tai ES, Morgenthaler NG, Seah LL, Fong KS, Chee SP, Choo CT, Aw SE 2000 Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 10:1093-1100.
11. Khoo DH, Ho SC, Seah LL, Fong KS, Tai ES, Chee SP, Eng PH, Aw SE, Fok AC 1999 The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 9:1175-1180.
12. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF 2000 Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol 52:267-271.
13. Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG 2006 Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464-3470.
14. Feliciello A, Porcellini A, Ciullo I, Bonavolonta G, Avvedimento EV, Fenzi G 1993 Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet 342:337-338.
15. Heufelder AE, Dutton CM, Sarkar G, Donovan KA, Bahn RS 1993 Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy. Thyroid 3:297-300.
16. Starkey K, Janezic A, Jones G, Jordan N, Baker G, Ludgate M 2003 Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol 30:369-380.
17. Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE 1998 Thyrotropin receptor expression in Graves' orbital adipose=connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 83:998-1002.
18. Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF 2003 TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol 58:280-287.
19. Bell A, Gagnon A, Grunder L, Parikh SJ, Smith TJ, Sorisky A 2000 Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. American Journal of Physiology: Cell Physiol 279:C335-C340.
20. Valyasevi RW, Erickson DZ, Harteneck DA, Dutton CM, Heufelder AE, Jyonouchi SC, Bahn RS 1999 Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab 84:2557-2562.
21. Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS 2002 Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 87:2352-2358.
22. Kumar S, Coenen MJ, Scherer PE, Bahn RS 2004 Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 89:930-935.
23. Kumar S, Leontovich A, Coenen MJ, Bahn RS 2005 Gene expression profiling of orbital adipose tissue from patients with Graves' ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis. J Clin Endocrinol Metab 90:4730-4735.
24. Stan MN, Coenen MJ, Bahn RS 2006 Adipogenesis is stimulated by thyrotropin receptor autoantibodies and TSH in Graves' orbital preadipocytes. Thyroid 16:859-860.
25. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P 1993 Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 16:251-257.
26. Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ 2003 Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 170:6348-6354.
27. Smith TJ, Hoa N 2004 Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 89:5076-5080.
28. Kodama K, Sikorska H, Bandy-Dafoe P, Bayly R, Wall JR 1982 Demonstration of a circulating autoantibody against a soluble eye-muscle antigen in Graves' ophthalmopathy. Lancet 2:1353-1356.
29. Hiromatsu Y, Cadarso L, Salvi M, Wall JR 1990 Significance of cytotoxic eye muscle antibodies in patients with thyroid-associated ophthalmopathy. Autoimmunity 5:205-213.
30. Hiromatsu Y, Sato M, Tanaka K, Shoji S, Nonaka K, Chinami M, Fukazawa H 1992 Significance of anti-eye muscle antibody in patients with thyroid-associated ophthalmopathy by quantitative western blot. Autoimmunity 14:9-16.
31. Kiljanski JI, Peele K, Stachura I, Pickeral J, Stolarski C, Kennerdell JS, Wall JR 1997 Antibodies against striated muscle, connective tissue and nuclear antigens in patients with thyroid-associated ophthalmopathy: should Graves' disease be considered a collagen disorder? J Endocrinol Invest 20:585-591.
32. Mizokami T, Salvi M, Wall JR 2004 Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon? J Endocrinol Invest 27:221-229.
33. De Bellis A, Perrino S, Coronella C, Sansone D, Ruocco G, Tirelli G, Di Martino S, Conte M, Bellastella G, Wall JR, Bellastella A, Bizzarro A 2004 Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease. Clin Endocrinol 60:694-698.
34. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW 2003 Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907- 1915.
35. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R 1997 IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195.
36. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA 2005 B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 44:1542-1545.
37. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, Edwards JC 2006 B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54:3612-3622.
38. Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA 2006 Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 65:942-945.
39. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC 2006 Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54:723-732.
40. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedus L 2006 Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 16:709-710.
41. Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P 2007 Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156:33-40.
42. Surmacz E 2003 Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 22:6589-6597.
43. Starkey K, Heufelder A, Baker G, Joba W, Evans M, Davies S, Ludgate M 2003 Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab 88:55-59.
44. Choy EH, Panayi GS 2001 Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916.